The Jackson Laboratory Acquires New York Stem Cell Foundation

The Jackson Laboratory Acquires Charles River Laboratories Japan Research Models & Services

October 12, 2021

Biotechnology

The Jackson Laboratory (JAX), a U.S.-based nonprofit biomedical research institution, has acquired Charles River Laboratories Japan's Research Models & Services (RMS) business as a wholly owned subsidiary. The Japan-based organization (renamed The Jackson Laboratory Japan) includes ~250 employees, three production sites in Atsugi, Hino and Tsukuba, and an administrative office in Yokohama.

Axol Bioscience Acquires Newcells Biotech's Ophthalmology Business

February 23, 2026

Biotechnology

Axol Bioscience has acquired the ophthalmology business of Newcells Biotech, including its specialist team, facilities, and intellectual property for iPSC-derived retinal organoid and retinal pigment epithelium models. The deal expands Axol's ophthalmology capabilities and product portfolio to support biopharma, biotech and CRO customers across Europe and the United States, strengthening its position in ophthalmology drug discovery and safety testing.

NLS Pharmaceutics Merges with Kadimastem to Form NewCelX

June 27, 2025

Biotechnology

NLS Pharmaceutics Ltd. completed a $3.0 million equity financing to support its pending merger with Kadimastem Ltd.; the transaction closed and the combined company was re-named NewCelX Ltd. The deal brings together NLS's CNS-focused pipeline and Kadimastem's cell therapy programs (AstroRx and IsletRx) to advance clinical development for ALS, diabetes and other regenerative-medicine indications.

QHP Capital Acquires Applied StemCell

October 9, 2023

Biotechnology

QHP Capital has acquired Applied StemCell, a Milpitas, California–based cell and gene therapy CRO/CDMO that provides iPSC and TARGATT gene‑editing platforms for biopharma and research clients. QHP said the acquisition will provide strategic capital and operating support to accelerate ASC's commercial expansion and scale its manufacturing and service capabilities for the cell and gene therapy market.

Axol Bioscience Acquires Phenocell

October 21, 2024

Biotechnology

Axol Bioscience Ltd. has fully acquired Phenocell SAS, adding Phenocell’s iPSC-derived skin and retinal cell lines and custom bioassay services to Axol’s drug discovery product portfolio. The acquisition expands Axol’s capabilities into ophthalmology and dermatology (including AMD and cosmetics testing); financial terms were not disclosed.

Discovery Life Sciences Acquires ReachBio Research Labs

April 11, 2023

Biotechnology

Discovery Life Sciences has acquired Seattle-based ReachBio Research Labs to expand its cell biology, toxicology and drug screening capabilities. The acquisition strengthens Discovery's preclinical development and multi-omics service offering, enabling customers to access a broader set of predictive cell-based assays for hematologic diseases, immunology, oncology and cell & gene therapy programs.